ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Adjuvant electronic brachytherapy for early-stage endometrial cancer: clinical outcomes, toxicity, and long-term local control.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeElectronic brachytherapy (eBT) is an emerging alternative to conventional Ir-192 HDR brachytherapy for adjuvant vaginal cuff irradiation. We evaluated long-term clinical outcomes, dosimetric parameters, and treatment-related toxicity in patients with early-stage endometrial cancer treated with adjuvant eBT.
methodsThis single-center retrospective study included 98 patients with early-stage endometrial cancer selected for adjuvant vaginal eBT between 2015 and 2019. Standard fractionation schedules were used. Dosimetric parameters, and acute and late toxicity graded according to CTCAE v5.0 were analyzed. Survival outcomes were assessed using Kaplan-Meier methodology. The median follow-up was 82.5 months.
resultsAdequate target coverage was achieved with a median D90 of 92.5% and median V100 of 80.5%. Mean cumulative D2cc doses were 13.3 Gy for bladder, 16.2 Gy for rectum, and 12.2 Gy for sigmoid colon. Acute toxicity was predominantly grade 1-2, with no grade ≥3 events. Grade 3 late toxicity occurred in three patients (3.1%). Vaginal cuff recurrence was observed in 3 patients (3.1%), resulting in a 7-year actuarial local control rate of 96.9%. Seven-year cancer-specific survival and overall survival were 94% and 85.7%, respectively.
conclusionsAdjuvant electronic brachytherapy provides favorable long-term local control with acceptable toxicity in selected patients with early-stage endometrial cancer. These findings support the feasibility of eBT for adjuvant vaginal cuff irradiation in appropriately selected clinical settings, although prospective comparative studies are needed to establish its role relative to conventional HDR brachytherapy.
Indexed as
Identifiers
42675340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.